<?xml version="1.0" encoding="UTF-8"?>
<p>The increasing employment of structurally related antimalarials to quinoline in massive treatments to eliminate viruses renders it necessary to study in detail their cardiovascular safety properties and to monitor and analyze the ECG during the treatment [
 <xref rid="B58-medicina-56-00386" ref-type="bibr">58</xref>]. This is further emphasized by the reported studies in patients with lupus erythematosus, where a relation between structural ECG abnormalities and cumulative antimalarial dose above the median (1207 g) were found [
 <xref rid="B59-medicina-56-00386" ref-type="bibr">59</xref>].
</p>
